Activities


  • Upcoming Activities
  • Past Activities

Upcoming activities will be listed in this section. For information on previous ILF events, please click on the "Past Activities" tab above.

2017

Global Accelerator for Paediatric Formulations (GAP-f): PADO webinar with regulators

Thursday, 15 June 2017, 14:00-15:00 CET

Partners involved in the development of the Global Accelerator for Paediatric Formulations (GAP-f) were invited to a short webinar to share, with government representatives and regulatory agencies, the key outcomes of a technical consultation held in December 2016 to prioritize development of paediatric ARV formulations (PADO 3 meeting).

This was an opportunity for an update on the broader work that WHO, in collaboration with key partners (including the IAS, through the ILF and CIPHER), is doing to accelerate development, approval and introduction of new paediatric formulations, in particular the GAP-f and key elements particularly related to regulatory matters.

Draft agenda:

  • Opening remarks
    Martina Penazzato (WHO) & Sébastien Morin (IAS)
  • GAP-f concept and plans
    George Siberry (OGAC)
  • Prioritization process and PADO3 outcomes
    Martina Penazzato (WHO)
  • Paediatric regulatory network and harmonization
    Emer Cooke (WHO)
  • Key elements for regulators
    Melynda Watkins (CHAI)
  • Questions and answers
    Sébastien Morin (IAS)

Download the webinar slide set




ILF/CIPHER Webinar: Report back from PADO 3

Tuesday, 28 February 2017, 16:00-17:00 CET

The ILF and CIPHER, in collaboration with WHO, held a webinar to disseminate the main outcomes from the Paediatric ARV Drug Optimization (PADO) 3 meeting - which took place during the Geneva Paediatrics Week. The webinar also included an update from the Paediatric ARV Working Group (PAWG).

The objectives of the PADO 3 meeting were as follows:

  1. Review medium- and long-term priorities for the development of new paediatric ARV drugs and formulations for paediatric HIV treatment and prevention
  2. Identify research gaps to be addressed and inform optimal use of ARVs in infants, children and adolescents to enable future development and uptake of priority products
  3. Identify synergies and promote alignment with drug and formulation development for other anti-infective agents to be used in paediatric hepatitis and tuberculosis.

This webinar followed from another webinar to report back from the paediatric week which the ILF and CIPHER held in December 2016 (watch the recording here).

To see the meeting agenda, click here
To listen and watch the recording for this webinar, click here

To see the speakers’ presentations, click on the links below:




2016

ILF/CIPHER Webinar: Report back from the paediatrics week

Thursday, 15 December 2016, 15:00-16:30 CET

The ILF and CIPHER held a webinar to disseminate, beyond stakeholders directly involved, the main outcomes of the Geneva paediatrics HIV week “Making the right drugs available for children with HIV”. Specifically, the webinar was focused on ensuring ARV manufacturers are kept informed of the latest developments in the paediatric ARV field.

To see the meeting agenda, click here
To listen and watch the recording for this webinar, click here

To see the speakers’ presentations, click on the links below:




CTA Meeting on Paediatric ARVs: Introducing the Global Accelerator for Paediatric Formulations

(by invitation only)
Monday, 5 December 2016
Geneva, Switzerland


On 5 December 2016, the Global Pediatric Antiretroviral Commitment-to-Action (CTA) partner organizations convened key stakeholders in the paediatric ARV space to accelerate joint efforts to identify innovative approaches to fast-track development and introduce priority paediatric formulations. This meeting built on previous efforts to develop a collaborative framework to accelerate development of paediatric ARVs, and, potentially, serve as a model for tuberculosis and other disease areas.

The objectives of the meeting were to first assess the level of stakeholder support for the revised proposal for a Global Accelerator for Paediatric Formulations and, second, provided the framework is supported, to identify and generate consensus around key action steps required for its implementation. To that end, the CTA convened leaders from across the HIV community and after presenting the revised framework, two panel discussions helped better define some of the concrete steps to be taken in order to start implementing the principles of the Global Accelerator for Paediatric Formulations, at global as well as at country level. Key considerations shared during the meeting are summarized and will be used to inform the next steps to be taken during the first phase of implementation of the Global Accelerator for Paediatric Formulations.

To see the meeting concept note for this closed meeting, click here
To see the meeting agenda for this closed meeting, click here
To see the list of participants for this closed meeting, click here

To see the speakers’ presentations, click on the links below:

  • Welcome
    George Siberry, Office of the U.S. Global AIDS Coordinator
  • Opening remarks
    Gottfried Hirnschall, World Health Organization
    Rev. Msgr. Robert J. Vitillo (Caritas Internationalis)
  • The Global Accelerator for Paediatric Formulations: Updated framework for collaboration
    Martina Penazzato (World Health Organization) Melynda Watkins (Clinton Health Access Initiative)
  • Open-floor discussion: Participant discussion of the Global Accelerator for Paediatric Formulations
    Facilitator: George Siberry, Office of the U.S. Global AIDS Coordinator
  • Panel discussion: Global actions to accelerate development and availability of key paediatric ARVs
    Facilitator: Carmen Perez Casas (UNITAID)
    Participants: Mark Lallemenat (DNDi), Yodit Belew (FDA)
    Elaine Abrams (IMPAACT), Devasena Gnanashanmugam (NIAID), Emmanuel Patras (Mylan Laboratories), Carlo Giaquinto (PENTA), Giancarlo Francese (Teva Pharmaceuticals), Helen McDowell (ViiV Healthcare)
  • Panel discussion: Increasing in-country demand and uptake
    Facilitator: Chip Lyons (Elizabeth Glaser Pediatric AIDS Foundation)
    Participants: Nandita Sugandhi (CHAI), Umesh Warty (CHAI), Fernando Pascual (MPP), Kedar Madhekar (Mylan Laboratories), Emer Cooke (WHO RHT)
  • Defining the next steps
    Marissa Vicari (International AIDS Society)
  • Summary and closing remarks
    Sébastien Morin (International AIDS Society)



ILF Thematic Roundtable on HIV Diagnostics: Addressing challenges of early infant diagnosis and point of care diagnostic

(By invitation only)
Tuesday, 19 July 2016
Durban, South Africa


In line with UNAIDS 90-90-90 targets, by 2020, 90% of all people living with HIV will know their HIV status, 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy, and 90% of all people receiving antiretroviral therapy will achieve viral suppression. Early infant diagnosis (EID) and the use of point of care (POC) diagnostics make integral parts of a strategy to achieve the first 90 (testing). However, challenges persist around evaluation of EID devices and quality assurance for POC diagnostic technologies.

The main objectives for this discussion are therefore to:

  1. Follow up on some of the issues highlighted at the ILF/CIPHER Thematic Roundtable on Paediatric HIV Diagnostics: Early Infant Diagnosis and Beyond (July 2015, Vancouver, meeting report available online), in particular:

    1. Challenges and progress in the area of clinical trials for EID devices
    2. Challenges related to the use of POC diagnostics and the role and challenges of connectivity
       
  2. Provide a platform for further brainstorming, exchange and discussion, highlight potential synergies, and catalyse collaboration among attendees from different backgrounds.

To see the meeting concept note for this closed meeting, click here
To see the meeting agenda for this closed meeting, click here
To see the list of participants for this closed meeting, click here
To see the meeting report for this closed meeting, click here
To see the speakers' presentations, click on the links below:




CTA/ILF/CIPHER Thematic Roundtable on Paediatric ARVs: Fast tracking development of priority ARV formulations

(By invitation only)
Saturday, 16 July 2016
Durban, South Africa


The global community has identified priorities for future development of paediatric ARV formulations through the Paediatric ARV Drug Optimization (PADO) consultations; however, there are many challenges to making these formulations available. Existing regulatory frameworks promote development of paediatric formulations, but implementation of those frameworks has been slow and sometimes inefficient. To help optimise global resources and efforts towards developing the most needed paediatric ARVs formulations, alternative models of collaborations and innovative financing mechanisms which build upon existing regulatory processes, optimize the investments in paediatric ARVs and enable a more sustainable development of prioritized products need to be explored. This requires promoting an open dialogue between key stakeholders such as drug manufacturers, policy makers, research networks, donors and regulatory agencies.

This meeting, convened by the Global Pediatric Antiretroviral Commitment-to-Action (CTA) and the International AIDS Society’s (IAS) Industry Liaison Forum (ILF) and Collaborative Initiative for Paediatric HIV Education and Research (CIPHER), followed up from the ILF/CIPHER Thematic Roundtable on Paediatric ARVs: Stimulating development of the most needed formulations, which took place on 7 March 2016 in Geneva, Switzerland. It also built upon the political commitment resulting from a high level dialogue on access to HIV testing and treatment which was convened by The Pontifical Council for Justice and Peace, UNAIDS, PEPFAR, and Caritas Internationalis in April 2016, as well as upon the ongoing work conducted on paediatric ARVs by the Pediatric HIV Treatment Initiative (PHTI), a partner of the CTA.

The set-up of the meeting was such that an open and interactive dialogue was promoted and supported to discuss opportunities for collaboration and develop a shared vision for making paediatric formulations suitable for low- and middle-income countries more quickly available.

To see the meeting concept note for this closed meeting, click here
To see the meeting agenda for this closed meeting, click here
To see the discussion points for this closed meeting, click here
To see the list of participants for this closed meeting, click here
To see the meeting report for this closed meeting, click here




To see the speakers' presentations, click on the links below:




ILF/CIPHER Thematic Roundtable on Paediatric ARVs: Stimulating development of the most needed formulations

(By invitation only)
Monday, 7 March 2016
Geneva, Switzerland


The global community has identified priorities for future R&D for paediatric ARV formulations through the Paediatric ARV Drug Optimization (PADO) meetings; however, there are many challenges in making these formulations available. Although coordinated procurement efforts have been successful in reducing market fragmentation, the paediatric market is small compared with the adult market, and manufacturers do not have incentives to develop these priority paediatric formulations. Existing regulatory frameworks promote development of paediatric formulations, but implementation of those frameworks may have resulted in inefficient allocation of resources for paediatric R&D. In addition, success in preventing mother-to-child transmission has reduced the number of new HIV infections, making it increasingly challenging to conduct robust clinical trials to assess efficacy, safety and acceptability of new paediatric drugs and fixed-dose combinations across the age spectrum.

For these reasons, alternative financing mechanisms must be explored to ensure availability of the best treatment for infants and children living with HIV in the future. These should build on existing regulatory processes, optimize the investment in paediatric ARVs, and enable a more sustainable development of prioritized products. This requires promoting open dialogue between manufacturers and key stakeholders, such as policy makers, research networks and regulatory agencies.

The main objectives for this discussion were therefore to:

  • Inform attendees from different backgrounds about the gaps between available and most needed paediatric ARV formulations
     
  • Share information on some existing innovative funding mechanisms and partnerships to support collaborative research and development between the public and private sectors
     
  • Brainstorm pragmatic approaches to addressing challenges for the rapid development of the most needed paediatric ARV formulations.

To see the meeting concept note for this closed meeting, click here
To see the meeting agenda for this closed meeting, click here
To see the list of participants for this closed meeting, click here
To see the meeting report, click here
To see the speakers' presentations, click on the links below:




2015

Discussion on opportunities for industry through EDCTP

(By invitation only)
Thursday, 22 October 2015
Webinar


The European & Developing Countries Clinical Trials Partnership (EDCTP, www.edctp.org) is a public-public partnership of 14 European and 14 sub-Saharan African countries supported by the European Union. Its mission is to accelerate the clinical development of effective, safe, accessible, suitable and affordable medical interventions for poverty-related diseases, in partnership with sub-Saharan Africa. To achieve this general objective EDCTP will strengthen international research collaboration with sub-Saharan African and will also actively seek to involve the private sector.

On the basis of competitive public calls for proposals, it funds the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as neglected (or emergent) infectious diseases including Ebola. All clinical trials from phase I-IV are funded (with a focus on phase II and III), including health systems optimisation research and capacity building (such as fellowships and support of research ethics review and regulatory capacity in sub-Saharan Africa).

The second EDCTP programme (2014-2024) is executed by the EDCTP Association as part of the European Framework Programme Horizon 2020. The European Union will contribute up to € 683 million for the 10-year programme, provided this is matched by contributions from the European members of the Association. To date, EDCTP2 calls for proposals have covered topics on diagnostics, treatment, large strategic trials and research capacity development, while future calls are expected to address additional gaps in treatment and prevention of HIV/AIDS and other poverty-related diseases in sub-Saharan Africa.

To see the presentation, click here




ILF/CIPHER PADO/IATT Update for ARV Manufacturers

(By invitation only)
Monday, 19 October 2015
Conference call


As part of the thematic roundtable series on paediatric ARVs, the ILF and CIPHER invited both generic and originator ARV manufacturers for a webinar focusing on some of the recent progress in the paediatric ARV space. The Paediatric ARV Drug Optimization (PADO) working group and the Interagency Task Team on the Prevention and Treatment of HIV Infection in Pregnant Women, Mothers and Children (IATT) took this opportunity to provide updates on the revision of the WHO 2013 Consolidated ARV Guidelines and the IATT Optimal List of Paediatric ARV Formulations. ARV manufacturers were able to stay up-to-date with this moving field and ask questions to members of these two working groups. For additional background information, please refer to the latest ILF/CIPHER Thematic Roundtable on Paediatric ARVs meeting report.

To see the meeting concept note and agenda for this closed meeting, click here
To see the list of participants for this closed meeting, click here
To see the speakers' presentations, click on the links below:




ILF activities at IAS 2015


  • ILF/CIPHER Thematic Roundtable on Paediatric HIV Diagnostics:
    Early Infant Diagnosis and Beyond
    (By invitation only)
    Sunday, 19 July 2015
    Vancouver, Canada


    From development to implementation, there are many challenges in paediatric HIV diagnostics. Indeed, although the 2013 WHO guidelines recommended testing infants at risk of perinatal HIV infection between 4-6 weeks by virological testing, there are discussions around testing at birth to ensure that treatment can start as soon as possible, especially before mortality peaks around three months. Beyond testing at birth and the PMTCT cascade, the diagnostics needs of infants and children will require integration in other healthcare platforms. As children age into adolescence and transition into adulthood, diagnostics will remain essential and, for treatment-experienced infected children, viral load monitoring and genotyping will become more important. It is hoped that this thematic roundtable will cover these and other issues bridging the industry, programming, regulatory and normative guidance spheres.

    This meeting started by looking at the paediatric diagnostics continuum, from development to implementation, highlighting challenges along the way and existing initiatives. An overview of WHO guidance as well as insights working-up to the next revision of the 2013 Consolidated Guidelines was also provided. The bulk of the time available was for a group discussion on creative solutions to overcome barriers to development and delivery of optimal paediatric HIV diagnostics.

    To see the meeting concept note for this closed meeting, click here
    To see the meeting agenda for this closed meeting, click here
    To see the list of participants for this closed meeting, click here
    To see the existing initiatives in Paediatric HIV Diagnostics, click here
    To see the meeting report for this closed meeting, click here

    To see the speakers' presentations, click on the links below:


    To view pictures of the meeting, click here
     
  • ILF/Co-Infections Thematic Roundtable on the Road to HCV Eradication
    (By invitation only)
    Monday, 20 July 2015
    Vancouver, Canada


    Dramatic treatment advances for HCV are taking place; direct acting antivirals represent opportunities to cure most HCV-infected individuals. These new therapies offer improvements in sustained virologic response rates, ease of administration, reduced toxicity and shortened duration of treatment, resulting in declarations that HCV could soon be eradicated. Lessons learned from the HIV epidemic will be critical in reaching this ultimate goal of eradicating HCV infection.

    This ILF/Co-Infections Thematic Roundtable took a step further from the 2nd International HIV/Viral Hepatitis Co-Infection Meeting (www.coinfectionmeeting.com) and focused on the development of a general, visionary and long-term agenda for HCV eradication. It addressed issues around (1) identifying of HCV-infected individuals and reaching key populations (particularly people who inject drugs and men who have sex with men); (2) establishing treatment priorities (e.g., whether or not to prioritize HIV/HCV co-infected individuals); (3) developing new financing models (particularly for middle-income countries); (4) supporting community empowerment; and (5) taking advantage of lessons learned from HIV.

    To see the meeting concept note for this closed meeting, click here
    To see the meeting agenda for this closed meeting, click here

    To see the speakers' presentations, click on the links below:


     
  • IAS-Industry Consultation on the Integration of HIV and Other Diseases:
    From Single Disease to Complete Patient Management
    (By invitation only)
    Tuesday, 21 July 2015
    Vancouver, Canada


    The increasing importance to strengthen health systems with integrated and coordinated approaches for HIV and other diseases is at the forefront of new objectives. Primary focus has been set upon the existing, but often “silent” tuberculosis (TB) integration, hepatitis C virus (HCV), and the emerging recognition of the increased burden in low and middle-income countries of non-communicable diseases (NCDs). These diseases often greatly affect PLHIV and their communities. Lessons learned from the HIV response are critical in reaching integration and strengthening of health systems in a sustainable manner. However, integration approaches must carefully assess the risks and benefits to existing structures, and consider all of the relevant stakeholders in implementation.

    The International AIDS Society (IAS)-Industry Consultation Series allows for strategic, high-level discussions between the IAS (Staff and Governing Council) and industry; this is an invaluable opportunity for industry, the IAS, and the global response to HIV. For IAS 2015, the IAS’s Industry Liaison Forum (ILF) has chosen to focus the IAS-Industry Consultation on the topic of integration of responses for HIV and other diseases (in particular TB, HCV and NCDs).

    This IAS-Industry Consultation on the Integration of HIV and Other Diseases: From Single Disease to Complete Patient Management provided a platform for participants to meet and discuss the challenges and opportunities to “bridge the gap” of integrated approaches, and health system strengthening between HIV and TB/HCV/NCDs. A keynote presentation set the stage and frame health system strengthening and integration from a HIV perspective, while an open, roundtable discussion allowed all participants to contribute to the exchange of ideas. The discussion covered issues around (1) Ongoing integration of HIV and TB: Is it working? (2) Upcoming integration of HIV and HCV: Are systems strong enough to cater for this integration? (3) Foreseen integration of HIV and NCDs: Will low and middle-income countries be ready? This included considerations on the impact of the flow of financing on product research and development and the overall integration of the response to multiple diseases.

    To see the meeting concept note for this closed meeting, click here
    To see the meeting agenda for this closed meeting, click here

    To see the speakers' presentations, click on the links below:

    • Introduction
      Kenneth Mayer (Fenway Institute, USA) – ILF Co-Chair
      Manuel Gonçalves (ViiV Healthcare, UK) – ILF Co-Chair
    • Presentation I: Health system strengthening and integration – The rationale
      Deborah Birx (PEPFAR, USA)
    • Presentation II: Health system strengthening and integration – The Brazilian perspective
      Fábio Mesquita (Department of STDs, AIDS and Viral Hepatitis, Brazil)
    • Roundtable discussion: Challenges and opportunities for integration of other diseases into the HIV response
      Facilitator: Catherine Hankins (Amsterdam Institute for Global Health and Development, The Netherlands) – ILF Advisory Group member

      1. Ongoing integration: HIV and TB - Is it working?
        Primary discussant: Alex Muganga Muganzi (Infectious Diseases Institute Makerere University College of Health Sciences, Uganda) – GC Member
      2. Upcoming integration: HIV and viral hepatitis - Are systems strong enough to cater for this integration?
        Primary discussant: Mauro Schechter (Universidade Federal do Rio de Janeiro, Brazil) - ILF Advisory Group member
      3. Foreseen integration: HIV and non-communicable diseases - Will low and middle-income countries be ready?
        Short introduction on NCDs - “Appendix NCDs
        Primary discussant: Stefano Vella (Istituto Superiore di Sanità, Italy) – ILF Advisory Group member
    • Summary and closing
      Kenneth Mayer (Fenway Institute, USA) – ILF Co-Chair
      Manuel Gonçalves (ViiV Healthcare, UK) – ILF Co-Chair
      Sébastien Morin (IAS, Switzerland) – ILF Research Officer

    To view pictures of the meeting, click here


ILF/CIPHER Thematic Roundtable on Paediatric ARVs

Aligning, coordinating and accelerating actions to provide better ARVs for children
Wednesday, 18 March 2015, 13:00‒17:00 CET
Geneva, Switzerland


Following the success of the roundtables on paediatric HIV that the IAS Industry Liaison Forum (ILF) and the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) held in Geneva, Switzerland, in November 2013 (see meeting report) and in Melbourne, Australia, in July 2014 (see meeting report), a follow-up roundtable on paediatric ARVs was organized. This meeting was an occasion to report on the recent progresses in the paediatric ARV space and to address some of the identified challenges in that field.

To see the concept note for this closed meeting, click here
To see the agenda for this closed meeting, click here
To see the list of participants for this closed meeting, click here
To see the evaluation report for this closed meeting, click here
To see the meeting report, click here

To see the speakers' presentations, click on the links below:



IAS-ILF Thematic Roundtable on Key Populations

Tuesday, 24 February 2015, 18:00‒22:30 PST
Seattle, WA, USA


To complement the work of the IAS’s KPs Priority, the IAS-ILF held a thematic roundtable on Key Populations (KPs). This event provided a space for a multi-stakeholder dialogue, serving as the basis to inform about the situation (i.e. raise mutual awareness), quantify the size of the problems and discuss interventions and organizations that can support existing efforts for wider access to HIV services, including through the creation of an enabling environment to end stigma and discrimination, for these difficult to reach populations and communities.

To see the concept note for this closed meeting, click here
To see the agenda for this closed meeting, click here
To see the list of participants for this closed meeting, click here
To see the evaluation report for this closed meeting, click here
To see the meeting report, click here

To see the speakers' presentations, click on the links below:



2014

IAS-ILF activities at AIDS 2014

  • IAS-ILF/CIPHER Thematic Roundtable on Paediatric HIV
    Saturday, 19 July 2014, 18:00-22:00, Melbourne, Australia

    Following the success of the IAS-ILF Industry Roundtable on Paediatric Antiretrovirals (ARVs), held in Geneva, Switzerland, in November 2013, a follow-up roundtable on paediatric HIV was held to widen the scope of the discussion from including mainly ARV manufacturers and international organizations to include investigators from the largest HIV paediatric cohorts worldwide (through the CIPHER cohort collaboration project).

    To see the meeting agenda for this closed meeting, click here
    To see the meeting report, click here
    To see the speakers' presentations, click on the links below:


     
  • IAS-Industry Consultation
    Tuesday, 22 July 2014, 18:30-22:00, Melbourne, Australia

    Following the success of the first IAS-Industry Consultation held in Boston, USA, in March 2014, the second IAS-Industry Consultation will take place in conjunction with AIDS 2014.

    To see the meeting agenda for this closed meeting, click here
    To see the list of participants, click here

    To see the IAS overview presentation by Bernard Kadasia (Deputy Executive Director and Director of Advocacy and Research Promotion), click here

IAS-ILF activity at INTEREST 2014

Symposium at the 8th International Workshop on HIV Treatment, Pathogenesis and Prevention Research in Resource-poor Settings (INTEREST 2014)

Expanding access to viral load monitoring in resource-limited settings
Monday, 5 May 2014, 16:00-18:00
Lusaka, Zambia

To see the meeting agenda, click here
To see the meeting report, click here
To see the speakers' presentations, click on the links below:


IAS-Industry Consultation

What is industry interested in and how can the IAS support it and benefit?
Fenway Health, Boston, USA
Tuesday, 4 March 2014, 18:30-22:00

This closed meeting was an occasion for the IAS to present its strategic priorities while getting insights from industry partners regarding their interests to foster further collaboration. Following short presentations by IAS Governing Council members and staff, the meeting was devoted to a roundtable discussion around industry partners’ interests and how the IAS can support industry and benefit from this interaction. The broad, high-level industry representation included ARV manufacturers, diagnostics companies, condom manufacturers and circumcision device manufacturers, companies involved in HIV cure and vaccine research, as well as implementers.

To see the meeting agenda, click here
To see the list of participants, click here

2013

Industry roundtable on paediatric ARVs

Paediatric antiretrovirals: The barriers to and solutions for improved access to optimal drugs in resource-limited settings
Wednesday, 27 November 2013, 09:00-13:00
Geneva, Switzerland

To see the meeting agenda, click here
To see the meeting report, click here
To see the speakers' presentations, click on the links below:


IAS-ILF activities at IAS 2013

Satellite sessions at the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013)

  • IAS-ILF -UNICEF satellite: Beyond Option B+
    Monday 1 July, 07:00-08:30 (Kuala Lumpur Convention Center)
    Co-chaired by Elly Katabira (IAS-ILF ) and Craig McClure (UNICEF)

    To see the agenda, click here
    To see the meeting report, click here
    To see the speakers' presentations, click on the links below:


  • IAS-ILF -AVAC satellite: Expanding HIV Prevention Options for Women
    Sunday 30 June, 17:00-19:00 (Kuala Lumpur Convention Center)
    Co-chaired by Linda-Gail Bekker (IAS-ILF ) and Mitchell Warren (AVAC)

    To see the agenda, click here
    To see the meeting report, click here
    To see the speakers' presentations, click on the links below:


IAS-ILF activity at CROI 2013

Affiliated event at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013)


2012

IAS-ILF activities at AIDS 2012

Public satellite meetings taking place in conjuction with the XIX International AIDS Conference in Washington D.C.:


IAS-ILF activity at CROI 2012

Pharmacology of ARVs: how HIV-1 infection differs in children and women
Monday, 5 March 2012, 12:00-15:30
Affiliated event at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)
Seattle, USA, 5-8 March 2012

To see the meeting agenda, click here
To see the meeting report, click here
To see the speakers’ presentations, click on the links below:

Pharmacology in Children Pharmacology in Women
  • From puberty to pregnancy: ARV pharmacology in women
    Mark Mirochnick (Boston U.)
  • Interaction of ARVs and hormonal contraceptives
    Kathleen Squires (Thomas Jefferson U.)
  • Women aging with HIV
    Kristine Patterson (U. of North Carolina)

2011

IAS-ILF activities at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention

Public satellite meetings taking place in conjuction with the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Rome, Italy:

  • Operational & implementation challenges in scaling up PMTCT programmes in resource limited settings
    Date/Time: 17 July 2011: 14:45-16:45
    Venue: Mini-Room 4
    Co-hosted with UNICEF

    To see the agenda, click here
    To see the meeting report, click here
  • Challenges in the development and procurement of paediatric antiretroviral formulations
    Date/Time: 17 July 2011: 17:00-19:00
    Venue: Mini-Room 4
    Co-hosted with UNICEF & Clinton HIV/AIDS Initiative (CHAI)

    To see the agenda, click here
    To see the meeting report, click here
  • What does the future of ARV-based prevention look like?
    Date/Time: 18 July 2011: 18:30-20:30
    Venue: Mini-Room 3
    Co-hosted with AVAC

    To see the agenda, click here
    To see the meeting report, click here

IAS-ILF activity at CROI 2011

Paediatric drug resistance in resource limited settings: jeopardising future treatment options
Sunday, 27 February 2011, 12:00-15:30

The 18th Conference on Retroviruses and Opportunistic Infections (CROI)
Boston, USA, 27 February - 2 March , 2011

To see the agenda, click here
To see the speakers’ presentations, click on the links below:
  • Results from P1060
    Paul Palumbo, Dartmouth Medical School, USA
  • Results from NEVEREST
    Louise Kuhn, Columbia University, USA
  • Acquired HIV Drug Resistance in children in Sub-Saharan Africa
    Gert van Zyl, Stellenbosch University, South Africa
  • Acquired HIV Drug Resistance in children in Asia
    Jintanat Ananworanich, The HIV Netherlands Australia Thailand, Research Collaboration HIV NAT, Thailand
  • Acquired HIV Drug Resistance in children – lessons from PENPACT1
    Diana Gibb, Medical Research Council, United Kingdom
  • Report back from WHO ResNet
    Silvia Bertagnolio, World Health Organization, Switzerland

2010

IAS-ILF activities at the XVIII International Conference

Scaling up early infant diagnosis of HIV as the bridge between prevention, care and treatment: successes, challenges and potential solutions
Sunday, 18 July 2010, 15:45-17:45

XVIII International AIDS Conference (AIDS 2010)

Vienna, Austria, 18-23 July 2010

To see the agenda, click here
To see the speakers' presentations, click on the links below:

The promise and perils of ARV-based prevention: making it a reality on the ground
Sunday, 18 July 2010, 15:45-17:45

XVIII International AIDS Conference (AIDS 2010)
Vienna, Austria, 18-23 July 2010

To see the agenda, click here
To see the powerpoint presentations, click on the links below:
Using antiretrovirals to prevent HIV: implications of the outcome of the CAPRISA 004 tenofovir-gel microbicide trial
Tuesday, 20 July 2010, 18:30-20:30

XVIII International AIDS Conference (AIDS 2010)

Vienna, Austria, 18-23 July 2010

To see the agenda, click here


Pediatric public-private partnership (by invitation only)
Wednesday, 21 July 2010, 07:00-08:30

XVIII International AIDS Conference (AIDS 2010)
Vienna, Austria, 18-23 July 2010

2009

Building consensus on clinical and operations research priorities for women and children
Sunday, 19 July 2009, 07:00-10:00

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2009)
Cape Town, South Africa, 19-22 July 2009

To see the agenda, click here
To see the IAS-ILF Mapping Exercise - Final Report (December 2009), click here
To see the IAS-ILF Mapping Exercise Summary Report July 2009), click here
To see the Draft Environmental Scan, click here
To see a webcast of this session, click here


The promise and perils of ARV-based prevention: a dialogue of informed optimism & skepticism - IAS-ILF /AVAC Satellite Meeting
Sunday, 19 July 2009, 14:45-18:00

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2009)
Cape Town, South Africa, 19-22 July 2009

To see the meeting overview and agenda, click here
To see a webcast of the session, click here
To read a session report, click here
To read more about the session, click here


Mapping gaps in clinical research in resource-limited settings: focus on paediatric treatment
Sunday, 8 February 2009, 08:30-11:30

The 16th Conference on Retroviruses and Opportunistic Infections (CROI)
Montreal, Canada, 8-11 February 2009

To see the meeting agenda, click here
To see the meeting report, click here
To see the speakers' presentations, follow the links below: 


2008

Industry and HIV clinical research – what is being learned in Africa? Focusing on women and children
Wednesday, 3 December 2008, 10:30-12:30

The 15th International Conference on AIDS and STIs in Africa
Dakar, Senegal, 3-7 December 2008

To see the meeting agenda, click here (also available in French)
To see the speakers' presentations, follow the links below:


The role of industry in development of ARV-based prevention technologies for women
Monday, 4 August 2008, 18:30-20:30

The XVII International AIDS Conference
Mexico City, Mexico, 3-8 August 2008

To see the meeting agenda, click here
To see photographs of the meeting, click here
To see the speakers' presentations, click on the links below:


Helping define a research agenda for women
Monday, 5 May 2008, 13:00-14:30

The Second Eastern Europe and Central Asia AIDS Conference (EECAAC)
Moscow, Russian Federation, 3-5 May 2008

To see the meeting agenda, click here
To see the Meeting Report, click here

Defining a research agenda for women in resource-poor countries
Sunday, 3 February 2008, 11:00-13:15

15th Conference on Retrovirus and Opportunistic Infections (CROI)
Boston, USA, 3-6 February 2008

To see the meeting agenda, click here
To see the meeting report, click here


2007

Defining industry responsibilities in Pre-exposure Prophylaxis (PReP) research and implementation
Sunday, 25 February 2007, 10:00-12:30

14th Conference on Retrovirus and Opportunistic Infections (CROI)
Los Angeles, USA, 25-28 February 2007

To see the meeting agenda, click here
To see the meeting report, click here

Are we prepared for PrEP? The challenges of implementing proven biomedical prevention technologies
Sunday, 22 July 2007, 08:00-10:00

4th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2007)
Sydney, Australia, 22-25 July 2007

To see the meeting agenda, click here


PrEP implementation policy forum: developing country-level preparation and capacity for PrEP implementation
Sunday, 22 July, 2007, 16:00-19:00

To see the meeting agenda, click here
To see the meeting report, click here 


2006

Scientific and investment considerations for research on Pre-exposure Prophylaxis (PrEP)
Sunday, 5 February 2006, 09:30-11:45

13th Conference on Retrovirus and Opportunistic Infections (CROI)
Denver, USA, 5-8 February 2006

To see the meeting agenda, click here
To see the meeting report, click here


What if Pre-exposure Prophylaxis (PrEP) works? The challenges of implementing new prevention technologies
Sunday, 13 August 2006, 12:30-14:30

The XVI International AIDS Conference
Toronto, Canada, 13-18 August 2006

To see the meeting agenda, click here


2005

IAS Industry Liaison Forum
Sunday, 22 February 2005

12th Conference on Retrovirus and Opportunistic Infections (CROI)
Boston, USA, 22-25 February 2005

To see the meeting report, click here